26844-12-2|Indoramin|N-[1-[2-(1H-indol-3-yl)ethyl]piperidin-4-yl]benzamide|-范德生物科技公司

Indoramin

NMR下载 COA and HPLC MSDS下载
names：
N-[1-[2-(1H-indol-3-yl)ethyl]piperidin-4-yl]benzamide
CAS号：
26844-12-2
MDL Number：
MF(分子式)： C22H25N3O MW(分子量)： 347.462
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Indoramin
英文别名	Indoramin; WY 21901; WY21901; WY-21901
CAS号	26844-12-2
Inchi	InChI=1S/C22H25N3O/c26-22(17-6-2-1-3-7-17)24-19-11-14-25(15-12-19)13-10-18-16-23-21-9-5-4-8-20(18)21/h1-9,16,19,23H,10-15H2,(H,24,26)
InchiKey	JXZZEXZZKAWDSP-UHFFFAOYSA-N
分子式 Formula	C22H25N3O
分子量 Molecular Weight	347.462
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Indoramin(CAS:26844-12-2):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Indoramin is an alpha-1 adrenergic antagonist that is commonly used as an antihypertensive agent.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Nelson RL, Thomas K, Morgan J, Jones A. Non surgical therapy for anal fissure. Cochrane Database Syst Rev. 2012 Feb 15;(2):CD00343[1]doi: 10.1002/14651858.CD003431.pub3. Review. PubMed PMID: 22336789.

[2]Kirsten R, Nelson K, Kirsten D, Heintz B. Clinical pharmacokinetics of vasodilators. Part II. Clin Pharmacokinet. 1998 Jul;35(1):9-36. Review. PubMed PMID: 9673832.

[3] Holmes B, Sorkin EM. Indoramin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and related vascular, cardiovascular and airway diseases. Drugs. 1986 Jun;31(6):467-99. Review. Erratum in: Drugs 1986 Oct;32(4):preceding 291. PubMed PMID: 3525084.

[4] Pierce DM. A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin. Xenobiotica. 1990 Dec;20(12):1357-67. Review. PubMed PMID: 1981634.

[5] Indoramin. Lancet. 1981 Jun 6;1(8232):1243-4. PubMed PMID: 6112572.

6: Seth L, Galiè N, Casebolt P, Gimenez H, Malloy M, Franciosa JA. Indoramin in heart failure: possible adverse effects on hemodynamics and exercise capacity. Clin Pharmacol Ther. 1986 Nov;40(5):567-74. PubMed PMID: 3769387.7: Bache RJ, Homans DC, Schwartz JS, Dai XZ. Differences in the effects of alpha-1 adrenergic blockade with prazosin and indoramin on coronary blood flow during exercise. J Pharmacol Exp Ther. 1988 Apr;245(1):232-7. PubMed PMID: 2896237.8: Digne-Malcolm H, Frise MC, Dorrington KL. How Do Antihypertensive Drugs Work? Insights from Studies of the Renal Regulation of Arterial Blood Pressure. Front Physiol. 2016 Jul 29;7:320. doi: 10.3389/fphys.2016.00320. eCollection 2016. Review. PubMed PMID: 27524972; PubMed Central PMCID: PMC4965470.9: Bennett JM, Weich DJ, Schoeman HS. Double-blind study comparing indoramin and propranolol in the treatment of black patients with hypertension. S Afr Med J. 1988 Dec 17;74(12):619-21. PubMed PMID: 3061032.10: Muller CA, Worthington MG, Thandroyen FT. Antiarrhythmic and metabolic effects of indoramin during acute regional ischemia and reperfusion in isolated rat heart. J Cardiovasc Pharmacol. 1990 Mar;15(3):408-13. PubMed PMID: 1691364.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开